Esperion Therapeutics (NASDAQ:ESPR) 公布其季度每股亏损$(0.11)，较分析师的共识预期$(0.16)高出31.25%。与去年同期每股亏损$(0.50)相比，这实现了78%的改善。公司季度销售额为$69.11M，超出分析师共识预期$61.58M，高出12.22%。与去年同期的销售额$32.25M相比，这增长了114.30%。

以上内容来自Benzinga Earnings专栏，原文如下：

Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.16) by 31.25 percent. This is a 78 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $69.11 million which beat the analyst consensus estimate of $61.58 million by 12.22 percent. This is a 114.30 percent increase over sales of $32.25 million the same period last year.